Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)